New insights into how blood clots: Implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 4, 1999, Pages 407-418

  Bajaj, S Paul ^a,b   Joist, J Heinrich ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

Author keywords

Activated partial thromboplastin time; Extrinsic coagulation; Intrinsic coagulation; Monitoring anticoagulant therapy; Prothrombin time

Indexed keywords

BLOOD CLOTTING FACTOR; THROMBOPLASTIN;

ANTICOAGULANT THERAPY; BLOOD CLOTTING; BLOOD VESSEL INJURY; FEEDBACK SYSTEM; FIBROBLAST; HUMAN; MONOCYTE; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SCREENING TEST; THROMBOCYTE;

EID: 0032758605     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994943     Document Type: Review

References (73)

1. Morawitz P. The Chemistry of Blood Coagulation. (German Edition 1905, English translation by RC Hartman and PF Guenther). Springfield, IL: Charles C Thomas; 1958
2. Schmidt A. Zur Blutlehre. Leipzig: Vogel; 1892
3. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-1312
4. MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature (London) 1964;202:498-499
5. Rapaport SI. Hemostatic mechanisms. In: Introduction to Hematology, 2nd Ed. Philadelphia: Lippincott; 1987:455
6. Bajaj MS, Ameri A, Bajaj SP. Tissue factor pathway inhibitor - A regulator of tissue factor induced coagulation. In: Green D, ed. Anticoagulants: Physiologic, Pathologic and Pharmacologic. Florida: CRC Press; 1994:41-65
7. Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII. Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977;74:5260-5264
8. Bajaj SP, Rapaport SI, Russell WA. Redetermination of the rate-limiting step in the activation of factor IX by factor XIa and by factor VIIa/tissue factor. Biochemistry 1983;22:4047-4053
9. Warn-Cramer BJ, Bajaj SP. Intrinsic versus extrinsic coagulation: Kinetic considerations. Biochem J 1986;239:757-762
10. Bauer KA, Kass BL, ten Cate H, Hawiger JL, Rosenberg RD. Factor IX is activated by the tissue factor mechanism. Blood 1990;76:731-736
11. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1-8
12. David EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991;30: 10363-10370
13. Bolton-Maggs PHB, Patterson DA, Wensley RT, Tuddenham EGD. Definition of the bleeding tendency in factor XI-deficient kindreds - A clinical and laboratory study. Thromb Haemost 1995;73:194-202
14. Ragni MV, Sinha D, Seaman F, et al. Comparison of bleeding tendency, factor XI coagulant activity and factor XI antigen in twenty-five factor XI deficient kindreds. Blood 1985; 65:719-724
15. Walsh PN, Baglia FA, Jameson BA. Factor XI and platelets: Activation and regulation. Thromb Haemost 1993;70:75-79
16. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XIa is activated by thrombin and factor XIa in the presence of negatively charged surface. J Biol Chem 1991;266:7353-7358
17. Gailani D, Broze GJ. Factor XI activation in a revised model of blood coagulation. Science 1991;253:909-912
18. Scott CF, Colman RW. Fibrinogen blocks the autoactivation of factor XI on dextran sulfate. Proc Natl Acad Sci USA 1992;89:11189-11193
19. von dem Borne PAK, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995;86:3035-3042
20. Cawthern KM, van 't Veer C, Lock JB, et al. Blood coagulation in hemophilia A and hemophilia C. Blood 1998;91:4581-4592
21. Oliver JA, Monroe DM, Roberts HR, Hoffman M. Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol 1998; (in press)
22. Colman RW, Scott CF. When and where is factor XI activated by thrombin? Blood 1996;87:2089-2091. Letter
23. Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF-VIIa complex in the cellular initiation of coagulation. Thromb Haemost 1997;78:401-405
24. Butenas S, Mann KG. Kinetics of human factor VII activation. Biochemistry 1996;35:1904-1910
25. Wildgoose P, Nemerson Y, Hansen LL, et al. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992;80:25-28
26. Eichinger S, Mannucci PM, Tradati F, et al. Determinants of plasma factor VIIa levels in humans. Blood 1995;86:3021-3025
27. Rao LVM, Williams T, Rapaport SI. Studies of activation of factor VII bound to tissue factor. Blood 1996;87:3738-3748
28. Nakagaki T, Foster DC, Berkner KL, Kisiel W. Initiation of the extrinsic pathway of blood coagulation: Evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry 1991;30:10819-10824
29. Neuenschwander PF, Fiore MM, Morrissey JH. Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. J Biol Chem 1993;268:21489-21492
30. Mann KG, Neshcim ME, Church WR, Haley P, Krishnaswamy S. Surface dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990;76:1-16
31. Morrissey JH, Neuenschwander PF, Huang Q. et al. Factor VIIa-tissue factor: Functional importance of protein-membrane interactions. Thromb Haemost 1997;78:112-116
32. Roberts HR, Hoffman M. Hemophilia and related conditions -inherited deficiencies of prothrombin (factor II), factor V, and factors VII to XII. In: Benther E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams' Hematology, 5th ed. New York: MacGraw-Hill; 1995:135-158
33. Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a "prima ballerina." Thromb Haemost 1995;74:7-17
34. Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 1995;86:1794-1801
35. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of blood coagulation. Annu Rev Med 1995;46:103-112
36. Lawson JH, Mann KG. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 1991;266:11317-11327
37. Lawson JH, Butenas S, Ribarik N, Mann KG. Complex dependent inhibition of factor VIIa by antithrombin III and heparin. J Biol Chem 1993;268:767-770
38. Rao LVM, Rapaport SI, Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 1993;81:2600-2607
39. Broze GJ Jr, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990;29: 7539-7544
40. Bajaj MS, Kuppuswamy MN, Galto H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990;87:8869-8873
41. Østerud B, Bajaj MS, Bajaj SP. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemost 1995;73:873-875
42. Van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD. Protease nexin-II (amyloid beta-protein precursor): A platelet alpha-granule protein. Science 1990;248:745-748
43. Smith RP, Higuchi DA, Broze GJ Jr. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990;248:1126-1128
44. Colman RW, Marder VJ, Salzman EW, Hirsh J. Overview of hemostasis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. Philadelphia: Lippincott; 1994:3-18
45. Dahlbäck B, Stenflo J. The protein C antiocoagulant system. In: Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H, eds. The Molecular Basis of Blood Disease. Philadelphia: Saunders; 1994:599-627
46. Esmon CT, Fukudome K. Cellular regulation of protein C pathway. Semin Cell Biol 1995;6:259-268
47. Koppelman SJ, van Hoeij M, Vink T, et al. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 1996;87:2292-2300
48. Loza J-P, Gurewich V, Johnstone M, Pannell R. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: A mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost 1994;71:347-352
49. Barna L, Triplett DA. Use of the activated partial thromboplastin time for the diagnosis of congenital coagulation disorders: Problems and possible solutions. Res Clin Lab 1989;19:345-354
50. Marlar RA, Bauer PJ, Endes-Brooks JL, et al. Comparison of the sensitivity of commercial APTT reagents in the detection of mild coagulopathies. Am J Clin Pathol 1984;82:436-439
51. Turi DC, Purschke EI. Sampling of three activated partial thromboplastin time reagents to coagulation factor deficiencies. Am J Clin Pathol 1986;85:43-49
52. Rapaport SI. Acquired coagulation disorders. In: Introduction to Hematology, 2nd ed. Philadelphia: Lippincott; 1987;541-557
53. Triplett DA. Screening for the lupus anticoagulant. Res Clin Lab 1989;19:379-389
54. Kitchen J, Preston FE. The therapeutic range for heparin therapy: Relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996;75: 734-739
55. Joist JH, Hyers T. Laboratory monitoring of heparin therapy. Thromb Forum 1995;1:1-4
56. Hirsh J, Levine MN. Low molecular weight heparin: Laboratory properties and clinical evaluation. A review. Eur J Surg 1194;571(suppl):9-22
57. White GC, Marder VJ, Colman RW, Hirsh J, Salzman EW. Approach to the bleeding patient. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. Philadelphia: Lippincott; 1994:1134-1147
58. Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983;61:684-692
59. Hemker HC, Veltkamp JJ, Loeliger EA. Kinetic aspects of the interaction of blood clotting enzymes. III. Demonstrations of an inhibitor of prothrombin conversion in vitamin K deficiency. Thrombosis et Diathesis Haemorrhagica 1968;19:346-351
60. Jensen R. Monitoring oral anticoagulant therapy. Clin Hemost Rev 1996;10:1-5
61. Sandset PM, Warn-Cramer BJ, Rao LVM, Maki SI, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991;88: 708-712
62. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: Potential therapeutic applications. Thromb Haemost 1997; 78:471-477
63. Rosen ED, Chan JCY, Idusogie E, et al. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 1997;390:290-293
64. Bugge TH, Xiao Q, Kombrinck KW, et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA 1996;93:6258-6262
65. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996;88:1583-1587
66. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383:73-75
67. Huang Z-F, Broze G Jr. Consequences of tissue factor pathway inhibitor gene-disruption in mice. Thromb Haemost 1997;78 699-704
68. Gailani D, Lasky NM, Broze GJ Jr. A murine model of factor XI deficiency. Blood Coag Fibrinolysis 1997;8:134-144
69. Colman RW, Schmaier AH. Contact system: A vascular modulator with anticoagulant, profibrinolytic, antiadhesive and proinflammatory attributes. Blood 1997;90:3819-3843
70. Ambrosini G, Altieri DC. Molecular dissection of effector cell protease receptor-1 recognition of factor Xa. Assignment of critical residues involved in antibody reactivity and ligand binding. J Biol Chem 1996;271:1243-1248
71. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994;269:26486-26491
72. Bajag MS, Kuppuswamy MN, Manepalli AN, et al. Transcriptional expression of tissue factor pathway inhibitor, Thrombomodulin, and von Willebrand factor in normal human tissues. Thrombos Haemostas 1999; (in press)
73. Bajaj MS, Steer S, Kuppuswamy MN, et al. Synthesis and expression of tissue factor way inhibitor by serum-stimulated fibroblasts, vascular smooth muscle cells, and cardiac myocytes. Thrombos Haemstas 1999; (in press)